Skip to main content
. 2019 Jul 12;7:114. doi: 10.1186/s40478-019-0759-6

Fig. 8.

Fig. 8

Disease progression is more severe in patients with lower CSF efnA5 protein levels. a Disease onset and b disease progression were determined in patients with CSF efnA5 levels above the median and in patients with CSF efnA5 levels below the median (N = 32). Differences were compared between the two genotypes with the Log-rank test: ** p < 0.01